A Rai

AG Tolcher

AX Zhu

Caio Max S Rocha-Lima

David Portnoy

DP Brooks

E Gabriela Chiorean

E Suzuki

J Albores-Saavedra

J Nelson

J Valle

JE Rogers

JF Guion-Dussere

Jitendra Gandhi

L Goyal

M Yanagisawa

Manik Amin

NV Rajeshkumar

P Papakostas

R Pazdur

Richard Kim

RK Jain

RL Siegel

S He

SC Lee

SY Oh

T Sasaki

T Walter

Tao Song

William P Harris

English

Crossref

British Journal of Cancer - Table 1 for article: Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatmenthttps://www.nature.com/bjc/journal/vaop/ncurrent/fig_tab/bjc2017160t1.html[7/9/2017 6:47:38 PM]nature.com Publications A-Z index Browse by subjectNext tableBACK TO ARTICLEJournal home > Advance online publication > 20 June 2017 > Full text > Table 1TABLE 1FROM:Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatmentRichard Kim, E Gabriela Chiorean, Manik Amin, Caio Max S Rocha-Lima, Jitendra Gandhi, William P Harris, Tao Song and David PortnoyTable 1. Demographics and baseline characteristicsFigures and tables indexBaseline characteristic SPI-1620 (N=30)Age (years) 30Mean (s.d.) 63.0 (9.94)Median 64Min, max 42, 80Gender   Female, n (%) 14 (46.7%) Male, n (%) 16 (53.3%)Ethnicity   Missing, n (%) 3 (10.0%) Hispanic or Latino, n (%) 2 (6.7%) Not Hispanic or Latino, n (%) 25 (83.3%)Race   Asian 1 (3.3%) Declined to answer 1 (3.3%) Declined to state 2 (6.7%) White 26 (86.7%)ECOG Performance Status   0 9 (30%) 1 20 (67%) 2 1 (3%)Primary site   Intrahepatic cholangiocarcinoma 22 (73%) Extrahepatic cholangiocarcinoma 7 (23%) Gallbladder cancer 1 (3%)Disease status   Locally advanced 2 (7%) Metastatic 28 (93%)Prior cancer surgery   Yes 16 (53%)My accountSubmit manuscriptRegisterSubscribeLogin CartSearch   Advanced searchWe use cookies to improve your experience with our site.Accept and close  | More info.British Journal of Cancer - Table 1 for article: Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatmenthttps://www.nature.com/bjc/journal/vaop/ncurrent/fig_tab/bjc2017160t1.html[7/9/2017 6:47:38 PM]Next tableBACK TO ARTICLEAbout usContact usAccessibility statementHelpPrivacy policyUse of cookiesLegal noticeTermsNaturejobsNature AsiaNature EducationRSS web feedsSearch:This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.British Journal of Cancer ISSN 0007-0920 EISSN 1532-1827© 2017 Cancer Research UK No 14 (47%)Prior chemotherapy   Gemcitabine+cisplatin 21 (70%) Gemcitabine+oxaliplatin 6 (20%) Gemcitabine 3 (10%) Abbreviation: ECOG=Eastern Cooperative Oncology Group.Figures and tables index partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef, COUNTER and COPE

British Journal of Cancer

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment

Kim, Richard

Chiorean, E. Gabriela

Amin, Manik

Rocha-Lima, Caio Max S

Gandhi, Jitendra

Harris, William P

Song, Tao

Portnoy, David

Digital Commons@Becker

https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=6972&amp;context=open_access_pubs

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment

Abstract

Similar works

Full text

Available Versions

Crossref

Digital Commons@Becker